Question 149 given in the Rajya Sabha on 20th August, 1990 and state:

(a) what are the details of various aspects concerning Drugs Prices Control Order being considered by Standing Committee;

(b) on which aspects the Standing Committee has sent recommendations to Government;

(c) what are the details of issues on which Government have taken the decision;

(d) what is the position of implementation of each decision;

(e) what are the names of drugs on which the Standing Committee has sent recommendations and on how many drugs decision has been sent;

(f) whether it is a fact that the Standing Committee is considering the issues of MAPE, Trade Commission, Profitability, Wholesale, Price Index, etc.;

(g) whether his Ministry has conducted any study on these aspects before these issues could be considered by the Standing Committee; and

(h) if so, what are the details thereof and if not, on what basis recommendations would be made ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) There are a number of issues like wrong exclusion of several bulk drugs from price control lists, exemption from price control to small scale units in respect of Category II formulations, inclusion of more drugs under price control etc. on which representations have been received by the Government. All these will be considered by the Standing Committee.

(b) to (e) The details of Government's decision taken so far on the recommendations made by the Standing Committee have been given in reply to Rajya Sabha Unstarred Question No. 899 dated 13-8-1990. These are at different stages of implementation. It is not in public interest to disclose the other recommendations of the Standing Committee at this stage.

(f) to (h) The Standing Committee will examine these issues independently for the review of the 1986 policy for which adequate data is available.

Price control on Hydroprogesterone and Glybenclamide

2950. DR. RATNAKAR PANDEY: SHRI RAJNI RANJAN SAHU:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1346 given in the Rajya Sabha on 20th August, 1990 and state:

(a) what was the sales turn over of Hydroprogesterone and Glybenclamide during the last three years, yearwise;

(b) what are the names of producers of both these drugs;

(c) since when the recommendations of Standing Committee in respect of these drugs are pending with the Government for decision and by when decision would be taken ;

(d) what are the names of other drugs for which decision on the recommendations of Standing Committee in respect of exclusion or inclusion of drugs is pending with Government for decision and by when decision on each would be taken;

(e) whether it is a fact that unnecessary loading of prices is being done by BICP on determination of fair prices of drugs; and

(f) if so, what are the details of such instances that came to the notice of his Ministry ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) The turnover in respect of Hydroprogesterone and Glybenclamide during the last three years is given in the Statement (*See* below).

(b) Name of the Bulk Drug	Name of the producer
(i) Hydroprogesterone	M/s. German Remedies
(ii) Glybenciamide	Ms. Hochest India Ltd.

(c) and (d) The recommendations of the Standing Committee in regard to inclusion and exclusion of certain drugs are still under consideration of the Government.

(e) and (f) BICP recommends the prices of bulk drugs after indepth study. The recommendations of the BICP are thoroughly examined before taking a decision on the prices of bulk drugs which are fixed from time to time.

Statement

(Value in Rs. lakhs)

	1986-87	1987-88	1988-89
(i) *Hydroprogester one*			
Imports	1.90	6.24	9.38
(ii) *Glybenclamide*			
Production	31.95	50.39	27.76
Imports	1.47	2.42	0.61
	33.42	52.81	28.37

Charging exorbitant prices on finished medicines by M/s. Infar

2951. DR. RATNAKAR PANDEY: SHRI RAJNI RANJAN SAHU :

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1410 given in the Rajya Sabha on 28th August, 1990 and state:

(a) what are the names of the companies which are producing the drugs which are also being produced by M/s. Infar and what is the selling price of each as intimated by each producer;

(b) what are the names of formulations based on these drugs being marketed by each and what is the annual sales turn over of each;

(c) what is the sales turn over of each drug of each producer